We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Q3 Earnings Tops, Revenues Miss Estimates
Read MoreHide Full Article
Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant Medtronic plc (MDT - Free Report) which has a global reach that extends to roughly 160 countries.
Currently, Medtronic has a Zacks Rank #3 (Hold) but that could change following its third-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.24 per share. Medtronic’s adjusted earnings per share of $1.29 exceeded this estimate by 4%.
Revenues: Medtronic posted revenues of $7.55 billion, missing the Zacks Consensus Estimate for revenues of $7.56 billion.
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 1.6% at constant exchange rate (CER) to $2.79 billion, revenues from Minimally Invasive Therapies Group increased 6.6% at CER to $2.12 billion. Also, revenues from Restorative Therapies Group rose 5.5% at CER to $2.03 billion, while revenues from Diabetes Group rose 6.5% at CER to $610 million.
Major Factors: Per management, third quarter performance was encouraging. Moreover, strength in the Minimally Invasive Therapies and Restorative Therapies Groups along with solid performance across emerging markets aided in offsetting several market-specific headwinds faced by the company during the reported quarter.
Stock Price: Following the earnings release, share prices rose by a 0.47% in the pre-market trading session till now.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Image: Bigstock
Medtronic (MDT) Q3 Earnings Tops, Revenues Miss Estimates
Are you a medical practitioner? Yes, then you must be aware of Minnesota-based one of the world’s leading medical technology giant Medtronic plc (MDT - Free Report) which has a global reach that extends to roughly 160 countries.
Currently, Medtronic has a Zacks Rank #3 (Hold) but that could change following its third-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.24 per share. Medtronic’s adjusted earnings per share of $1.29 exceeded this estimate by 4%.
Revenues: Medtronic posted revenues of $7.55 billion, missing the Zacks Consensus Estimate for revenues of $7.56 billion.
Medtronic PLC Price and EPS Surprise
Medtronic PLC Price and EPS Surprise | Medtronic PLC Quote
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 1.6% at constant exchange rate (CER) to $2.79 billion, revenues from Minimally Invasive Therapies Group increased 6.6% at CER to $2.12 billion. Also, revenues from Restorative Therapies Group rose 5.5% at CER to $2.03 billion, while revenues from Diabetes Group rose 6.5% at CER to $610 million.
Major Factors: Per management, third quarter performance was encouraging. Moreover, strength in the Minimally Invasive Therapies and Restorative Therapies Groups along with solid performance across emerging markets aided in offsetting several market-specific headwinds faced by the company during the reported quarter.
Stock Price: Following the earnings release, share prices rose by a 0.47% in the pre-market trading session till now.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>